Mayne Pharma names Frank Condella board chair
Mayne Pharma has made two new board appointments. Frank Condella will become chairman, effective Sept. 30, while Ian Scholes will be appointed deputy chairman.
Condella and Scholes currently are independent directors of Mayne Pharma.
Roger Corbett, chairman and Bruce Mathieson, non-executive director will step down from the board following the September board meeting.
Corbett has served as a director of Mayne Pharma since 2010 and as chairman since January 2011. Mathieson has served as a director since 2007.
[Read more: Rolling with the punches: Generics firms innovate, expand scope to stay competitive]
“It has been a great privilege and honor to serve as chairman of Mayne Pharma over the last ten years. On behalf of the board,” Corbett said. “I want to thank Bruce for his significant contribution and service to Mayne Pharma. Bruce has provided insightful guidance and unwavering support to the company as it journeyed from a small biotech to a diversified specialty pharmaceutical company. I am confident that the new Board structure under Frank’s guidance will support our management team to achieve our strategic goals.”
Corbett noted that a new director nominated by partner in commercializing the new contraceptive Nextstellis, Mithra Pharmaceuticals, is expected to be appointed to the board prior to the 2021 Annual General Meeting.
Condella said, “On behalf of the board, I thank Roger for his significant contribution and ten years of service to Mayne Pharma. I am pleased to accept the role of chairman at Mayne Pharma. After several challenging years, Mayne Pharma is well positioned to capitalize on a number of significant near term growth opportunities including the recently approved Nextstellis oral contraceptive and the strengthened pipeline of dermatology and women’s health products. I look forward to continue working with the Mayne Pharma Board and leadership team as we embark on a new chapter of growth.”